Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gene Signal International SA

Latest From Gene Signal International SA

Gene Signal Novel Corneal Neovascularization Product Still On Track Despite Primary Endpoint Miss

Although visual acuity is no longer thought to be a useful primary endpoint for drugs targeting corneal neovascularization, Gene Signal will keep developing its first-in-class antisense product in that and other ophthalmic indications.

BioPharmaceutical Europe

Gene Signal Will Expand Antisense Ophthalmic Studies With New Funds

A topical antisense product, aganirsen, from Switzerland’s Gene Signal is to be evaluated in neovascular glaucoma, age-related macular degeneration and psoriasis following the completion of a Phase III study in corneal graft rejection.

BioPharmaceutical Business Strategies

Recent Financings Of Private Companies, February 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Start-Ups column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.

BioPharmaceutical Medical Device

Gene Signal outlines 'aggressive' three-year plan as it completes latest funding round

Having completed its latest private funding round, Lausanne, Switzerland-based biotech firm, Gene Signal said it is set to embark on an 'aggressive' three-year clinical and commercialization plan for its angiogenesis therapies.

Dermatology Cancer
See All

Company Information

  • Industry
  • Biotechnology